Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 63 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Histidine Clear all
Recruiting Phase 2 Interventional

Neurovascular Transduction During Exercise in Chronic Kidney Disease

NCT02947750
View directory record Official record
Conditions
Renal Insufficiency, Chronic
Interventions
6R-BH4, 6R-BH4 placebo, Folic acid, Exercise training, Stretching, Histidine and beta-alanine supplementation, Histidine and beta-alanine placebo
Drug · Other · Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 2, 2026, 10:14 PM EDT
Completed No phase listed Observational

Non-Invasive Assessment of Skeletal Muscle Loss in Cancer Patients - Phase II

NCT01694602
View directory record Official record
Conditions
Cachexia
Interventions
(non-radioactive) Oral deuterated 3-methylhistidine (D-3MH)
Biological
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Sep 2, 2026, 10:14 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy

NCT02966314
View directory record Official record
Conditions
Idiopathic Angioedema
Interventions
Omalizumab, Placebos
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Sep 2, 2026, 10:14 PM EDT
Active, not recruiting Phase 2 Interventional

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

NCT06172127
View directory record Official record
Conditions
HER2-positive Breast Cancer
Interventions
Trastuzumab deruxtecan, Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection, Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection
Drug
Lead sponsor
MedSIR
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 2, 2026, 10:14 PM EDT
Terminated Phase 1Phase 2 Interventional

Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO)

NCT04120883
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Hydroxychloroquine lower dose, Hydroxychloroquine higher dose
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 25, 2024 · Synced Sep 2, 2026, 10:14 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination

NCT04722003
View directory record Official record
Conditions
Gonorrhoea
Interventions
Meningococcal Group B Vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Sep 2, 2026, 10:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Muscle Regrowth During Physical Rehabilitation and Amino Acid Supplementation

NCT00760383
View directory record Official record
Conditions
Osteoarthritis
Interventions
Essential amino acids, Alanine
Dietary Supplement
Lead sponsor
University of Oregon
Other
Eligibility
60 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
2
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Sep 2, 2026, 10:14 PM EDT
Recruiting Phase 2 Interventional

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

NCT05428007
View directory record Official record
Conditions
Melanoma, Unresectable Melanoma
Interventions
Sarilumab, Ipilimumab Injection, Nivolumab/Relatlimab
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Sep 2, 2026, 10:14 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Prandial Metabolic Phenotype in Adults

NCT05400733
View directory record Official record
Conditions
Protein Metabolism
Interventions
Total Amino Acids, Essential Amino Acids, Essential Amino Acids + Hydroxy-methylbutyric acid (HMB), Essential Amino Acids + Leucine, Essential Amino Acids High, Placebo Water
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
60 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 2, 2026, 10:14 PM EDT
Recruiting Phase 2 Interventional

The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD

NCT05440422
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Cardiovascular Disease, Premature Atherosclerosis
Interventions
anifrolumab, Placebo
Drug · Other
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 2, 2026, 10:14 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Histaminergic Basis of Fatigue in Multiple Sclerosis

NCT04764383
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
L-Histidine, Placebo, Lodosyn
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Sep 2, 2026, 10:14 PM EDT
Completed Phase 1 Interventional

A Study of Patients With Chronic Kidney Disease to Assess the Safety of a Single Dose of COR-001

NCT03126318
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
COR-001, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Sep 2, 2026, 10:14 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of Rezafungin

NCT04117607
View directory record Official record
Conditions
Fungal Infection
Interventions
Placebo, Rezafungin
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Sep 2, 2026, 10:14 PM EDT
Completed Phase 1 Interventional

Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT02277197
View directory record Official record
Conditions
Carcinoma, Squamous Cell of Head and Neck, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head And Neck
Interventions
Ficlatuzumab, Cetuximab
Drug
Lead sponsor
James J Lee
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Sep 2, 2026, 10:14 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study of Intravenous ZMA001 in Healthy Subjects

NCT05967299
View directory record Official record
Conditions
Pulmonary Arterial Hypertension PAH
Interventions
Placebo Cohort 1 (1.5 mg/kg/dose) only, ZMA001 (BC-NKA-20008)
Other · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 60 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 2, 2026, 10:14 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S

NCT01556945
View directory record Official record
Conditions
Malaria, Falciparum
Interventions
FMP1/AS02, RTS,S/AS02, AS02 adjuvant alone, Malaria challenge
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2001
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Sep 2, 2026, 10:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Chronic Obstructive Pulmonary Disorder and Acute Exercise

NCT02780219
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
stable amino acid infusion, acute exercise with amino acid infusion, 24-hour post exercise amino acid infusion
Other
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years and older
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 2, 2026, 10:14 PM EDT
Completed Phase 3 Interventional

Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency

NCT00811785
View directory record Official record
Conditions
Menkes Disease, Occipital Horn Syndrome, Unexplained Copper Deficiency
Interventions
Copper Histidine
Drug
Lead sponsor
Cyprium Therapeutics, Inc.
Industry
Eligibility
Up to 80 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Sep 2, 2026, 10:14 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Clinical Study on Rapid Antioxidant Protection and Immune Modulating Effects.

NCT05042674
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Placebo, Ergothioneine, 25 miligrams, Ergothioneine, 25 miligrams, daily for 1 week
Dietary Supplement
Lead sponsor
Natural Immune Systems Inc
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Klamath Falls, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Sep 2, 2026, 10:14 PM EDT
Completed Phase 1Phase 2 Interventional

A Randomized Study to Evaluate the Safety and Efficacy of Various Doses of STP705 in Subjects With Hypertrophic Scar

NCT02956317
View directory record Official record
Conditions
Hypertrophic Scar
Interventions
STP705, Placebo
Drug
Lead sponsor
Sirnaomics
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Sep 2, 2026, 10:14 PM EDT
Withdrawn Phase 4 Interventional

Histidine Oral Supplementation as a Therapeutic Modality for Alzheimer's Disease

NCT06169826
View directory record Official record
Conditions
Alzheimer Disease
Interventions
l-Histidine, Control
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 2, 2026, 10:14 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19

NCT04343651
View directory record Official record
Conditions
Coronavirus Disease 2019
Interventions
Placebo, Leronlimab (700mg)
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
12
States / cities
Los Angeles, California • Palm Springs, California • Rancho Mirage, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 2, 2026, 10:14 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults

NCT07197762
View directory record Official record
Conditions
Neisseria Meningitidis
Interventions
Trumenba, PENBRAYA
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 25 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 2, 2026, 10:14 PM EDT
Completed Phase 2 Interventional Results available

Mechanistic Approach to Preventing Atrophy and Restoring Function in Older Adults

NCT02145949
View directory record Official record
Conditions
Muscle Atrophy, Quality of Life
Interventions
Essential Amino Acids (EAA), Placebo (Alanine)
Drug
Lead sponsor
University of Oregon
Other
Eligibility
50 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Sep 2, 2026, 10:14 PM EDT